Emilio Bajetta

Active 1972–2025

59
Papers
21,135
Citations
56
h-index
59
i10-index

Citations

Citations per year for Emilio Bajetta1974: 1 citations1975: 1 citations1976: 3 citations1977: 12 citations1978: 8 citations1979: 8 citations1980: 8 citations1981: 7 citations1982: 4 citations1983: 13 citations1984: 2 citations1985: 5 citations1986: 6 citations1987: 3 citations1988: 4 citations1989: 5 citations1990: 8 citations1991: 5 citations1992: 6 citations1993: 3 citations1994: 5 citations1995: 7 citations1996: 8 citations1997: 6 citations1998: 14 citations1999: 28 citations2000: 45 citations2001: 52 citations2002: 74 citations2003: 100 citations2004: 131 citations2005: 182 citations2006: 162 citations2007: 166 citations2008: 203 citations2009: 234 citations2010: 276 citations2011: 266 citations2012: 185 citations2013: 192 citations2014: 148 citations2015: 123 citations2016: 136 citations2017: 102 citations2018: 104 citations2019: 286 citations2020: 264 citations2021: 198 citations2022: 125 citations2023: 114 citations2024: 174 citations2025: 65 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,707 citing papers, 26.2% of this breakdownItaly: 548 citing papers, 8.4% of this breakdownUnited Kingdom: 506 citing papers, 7.7% of this breakdownFrance: 383 citing papers, 5.9% of this breakdownGermany: 365 citing papers, 5.6% of this breakdownChina: 307 citing papers, 4.7% of this breakdownCanada: 255 citing papers, 3.9% of this breakdownNetherlands: 215 citing papers, 3.3% of this breakdownSpain: 212 citing papers, 3.2% of this breakdownSwitzerland: 209 citing papers, 3.2% of this breakdownBelgium: 200 citing papers, 3.1% of this breakdownJapan: 176 citing papers, 2.7% of this breakdown
0%26.2%Other 22.1%

Fields

  • Medicine68.9%
  • Biochemistry, Genetics and Molecular Biology23%
  • Immunology and Microbiology4.8%
  • Materials Science0.5%
  • Mathematics0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other1.8%

Topics

  • Colorectal Cancer Treatments and Studies5.7%
  • Estrogen and related hormone effects3.6%
  • Breast Cancer Treatment Studies3.5%
  • Renal cell carcinoma treatment3.5%
  • Neuroendocrine Tumor Research Advances3.1%
  • Cancer Treatment and Pharmacology3%
  • Other77.6%

Coauthors

All papers

Open in search
  1. Interleukin-12: Biological Properties and Clinical Application

    Authors: , , , , , , - Clinical Cancer Research 2007 cited by 604

  2. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 cited by 526

  3. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Authors: , , , , , , , , , , , , , , - The Lancet 2007 cited by 2,223

  4. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ettore Seregni, Marco Maccauro, Secondo Lastoria, Alberto Bongiovanni, Annibale Versari, Irene Persano, Maria Rinzivillo, Salvatore Antonio Pignata, Paola Rocca, Giuseppe Lamberti, Sara Cingarlini, Ivana Puliafito, Maria Rosaria Ambrosio, Isabella Zanata, Alessandra Bracigliano, Stefano Severi, Francesca Spada, Valentina Andreasi, Roberta Modica, Federica Scalorbi, Massimo Milione, Giovanna Sabella, Jorgelina Coppa, Riccardo Casadei, Maria Di Bartolomeo, Massimo Falconi, Filippo de Braud - JAMA Network Open 2022 cited by 59

  5. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathy D. Miller, Patrick G. Morris, Elisabetta Munzone, Einav Nili Gal‐Yam, Alistair Ring, Lois E. Shepherd, Christian F. Singer, Christoph Thomssen, Ling‐Ming Tseng, Pinuccia Valagussa, Eric P. Winer, Antonio C. Wolff, Gabriele Zoppoli, Jana Machacek‐Link, Céline Schurmans, Xin Huang, Eric Gauthier, Christian Fesl, Amylou C. Dueck, Angela DeMichele, Michael Gnant, on behalf of the PALLAS Groups and Investigators, David Cameron, Sarra El-Abed, Hope S. Rugo, Guenther G. Steger, Tiffany A. Traina, Gustavo Werutsky, Norman Wolmark - Journal of Clinical Oncology 2023 cited by 34

  6. Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

    Authors: , , , , , , , , , , - New England Journal of Medicine 1976 cited by 1,334

  7. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet 2009 cited by 1,355

  8. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anna La Salvia, Nicole Brighi, Annamaria Colao, Ivana Puliafito, Francesco Panzuto, Silvia Ortolani, Alberto Zaniboni, Francesco Di Costanzo, Mariangela Torniai, Emilio Bajetta, Salvatore Tafuto, Silvio Ken Garattini, Daniela Femia, Natalie Prinzi, Laura Concas, Giuseppe Lo Russo, Massimo Milione, Luca Giacomelli, Roberto Buzzoni, Gianfranco Delle Fave, Vincenzo Mazzaferro, Filippo de Braud - Gastroenterology 2018 cited by 89

  9. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2001 cited by 1,036

  10. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2004 cited by 1,767

  11. Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Einav Nili Gal‐Yam, Xavier González, Ling‐Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Ivan Sinielnikov, Zimina Anastasia, Aleksandr Vasiliev, E. Shearer-Kang, Eric S. Winer, Diogo Martins-Branco, Shona Fielding, David Cameron, Giuseppe Viale, Shigehira Saji, Richard D. Gelber, Martine Piccart - Cancer Research 2024 cited by 13

  12. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

    Authors: , , , , , , , , , , , , - The Lancet 1998 cited by 993

  13. Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Authors: , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 808

  14. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 591

  15. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

    Authors: , , , , , , , , , , , , , , , , , - Annals of Oncology 2002 cited by 524

  16. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

    Authors: , , , , , , , , , , , , , - Annals of Oncology 2008 cited by 414

  17. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

    Authors: , , , , , , , , , , - Cancer Chemotherapy and Pharmacology 2006 cited by 241

  18. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

    Authors: , , , , , , , , , , - The Lancet Oncology 2008 cited by 238

  19. Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 139

  20. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric S. Winer, David Cameron, G. Viale, Shigehira Saji, Richard D. Gelber, Martine Piccart - JAMA 2025 cited by 40

  21. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

    Authors: , , , , , - Journal of Clinical Oncology 2001 cited by 977

  22. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E Colajori, Milayna Subar, Elizabeth Ireland, Judith M. Bliss - The Lancet 2007 cited by 909

  23. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

    Authors: , , , , , , , - Cancer 1996 cited by 296

  24. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors

    Authors: , , , , , , , , , - Cancer 1999 cited by 289